Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02663518
Recruitment Status : Recruiting
First Posted : January 26, 2016
Last Update Posted : August 9, 2019
Sponsor:
Information provided by (Responsible Party):
Trillium Therapeutics Inc.

Brief Summary:
Multicenter, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.

Condition or disease Intervention/treatment Phase
Hematologic Malignancies Solid Tumor Drug: TTI-621 Drug: TTI-621 plus Rituximab Drug: TTI-621 plus Nivolumab Phase 1

Detailed Description:

This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.

TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (anti phagocytic) signal to macrophages.

This trial will be conducted in 2 phases and 4 parts: Phase 1a Part 1 (escalation phase) and Phase 1b Parts 2-4 (expansion phase).

In the dose Escalation Phase (phase 1a Part 1), subjects with lymphoma will be enrolled in sequential dose cohorts to receive TTI-621 to characterize safety, tolerability, pharmacokinetics, and the maximum-tolerated dose (MTD).

In the Expansion Phase (phase 1b Parts 2-4), TTI-621 will be given to subjects with a variety of hematologic malignancies and selected solid tumors to further define safety and to characterize efficacy. In the Expansion Phase Part 2, the safety and efficacy of TTI-621 will also be assessed when it is given in combination with other anti-cancer drugs. The dose of TTI-621 to be delivered in the Expansion Phase Parts 2-3 of the study may be increased or decreased based on the subject's tolerability and on the subject's response to treatment.

In the phase 1b dose optimization of the study (Part 4), further dose escalation of TTI-621, beyond the dose determined during phase 1a dose escalation, will be pursued in patients with relapsed and/or refractory CTCL following a 3+3 escalation design and using a revised DLT criteria to further evaluate the safety and tolerability of TTI-621 at dose levels higher than the initially recommended phase 1b Parts 2-3.

Secondary objectives include further characterization of the pharmacokinetics, pharmacodynamics, and development of ADA; and to gain preliminary evidence of the anti-tumor activity of TTI-621 in subjects with a variety of hematologic malignancies and selected solid tumors. In addition, the safety of TTI-621 will be evaluated in combination with other anti-cancer agents.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 260 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Masking Description: Open label
Primary Purpose: Treatment
Official Title: A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors
Actual Study Start Date : January 2016
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2021


Arm Intervention/treatment
Experimental: TTI-621 Escalation Phase
The Escalation Phase will include multiple doses of TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Indolent B-Cell Lymphoma
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Aggressive B-Cell Lymphoma
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: T-Cell Lymphoma
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Hodgkin Lymphoma
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Chronic Lymphocytic Leukemia
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Acute Lymphoblastic Leukemia
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Multiple Myeloma
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Acute Myeloid Leukemia
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Myelodysplastic Syndrome
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Myeloproliferative Neoplasms
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Small Cell Lung Cancer
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Rituximab Combination
Combination therapy expansion cohort with TTI-621 plus Rituximab for CD20 positive malignancies
Drug: TTI-621 plus Rituximab
Combination therapy
Other Name: TTI-621 plus Rituxan

Experimental: Nivolumab Combination
Combination therapy expansion cohort with TTI-621 plus Nivolumab for Hodgkin Lymphoma
Drug: TTI-621 plus Nivolumab
Combination therapy
Other Name: TTI-621 plus Opdivo

Experimental: Cutaneous T-Cell Lymphoma (CTCL)
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Peripheral T-Cell Lymphoma (PTCL)
Monotherapy expansion cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc

Experimental: Part 4: Cutaneous T-Cell Lymphoma (CTCL)
Monotherapy expansion Part 4 (Dose Optimization) cohort with TTI-621
Drug: TTI-621
Monotherapy
Other Name: SIRPαFc




Primary Outcome Measures :
  1. Incidence and severity of adverse events [ Time Frame: 42 months ]

    Safety and tolerability of TTI-621 when given alone and in combination with other anti-cancer agents to subjects with a variety of hematologic malignancies and with selected solid tumors, and to evaluate the safety of a standardized intra-subject TTI-621 dose intensification schedule.

    Part 4: To further evaluate the safety and tolerability of TTI-621 at dose levels higher than the initially recommended phase 1b Parts 2 and 3 dose and to reassess the MTD and/or recommended phase 2 dose per revised DLT criteria following a 3+3 dose escalation schema.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Advanced measurable malignancy
  2. Adequate hematologic status
  3. Relapsed or are refractory following at least 2 prior systemic therapeutic attempts (1 prior systemic attempt for PTCL). For CTCL, extracorporal photochemotherapy (ECP) will be considered a systemic therapy. Local radiation and topical agents are not systemic therapies.
  4. Adequate coagulation function
  5. Adequate hepatic function
  6. Adequate renal function

Exclusion Criteria:

  1. Known, current central nervous system disease involvement or untreated brain metastases
  2. Allogeneic transplant within 30 days prior to the planned start of treatment or subjects with active graft-vs-host disease with the exception of Grade 1 skin involvement
  3. History of hemolytic anemia or bleeding diathesis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02663518


Contacts
Layout table for location contacts
Contact: Kathleen Roberge, NP-C, MSN, MSc 857-412-7029 ext 211 kathleen@trilliumtherapeutics.com
Contact: Yaping Shou, MD, PhD yaping@trilliumtherapeutics.com

Locations
Layout table for location information
United States, California
City of Hope National Medical Center Recruiting
Duarte, California, United States, 91010
Contact: Matthew Mei       mamei@coh.org   
Stanford Cancer Institute Recruiting
Palo Alto, California, United States, 94304
Contact: Sophia Fong       sophiafong@stanford.edu   
United States, Colorado
Colorado Blood Cancer Institute Recruiting
Denver, Colorado, United States, 80218
Contact    877-691-7274    asksarah@sarahcannon.com   
United States, Florida
Mayo Clinic Recruiting
Jacksonville, Florida, United States, 32224
Contact: Christopher Lyons    904-953-6826    Lyons.Christopher@mayo.edu   
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Stephen Ansell    855-776-0015    ansell.stephen@mayo.edu   
United States, New Jersey
Hackensack Meridian Health John Theurer Cancer Center Recruiting
Hackensack, New Jersey, United States, 07601
Contact: Kara Yannotti    551-996-5168    Kara.Yannotti@hackensackmeridian.org   
United States, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health Recruiting
New York, New York, United States, 10016
Contact: Angela Tan    646-501-7869    Angela.Tan@nyumc.org   
Columbia Univeristy Recruiting
New York, New York, United States, 10019
Contact: Freddy J. Loffredo       fl2156@cumc.columbia.edu   
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Steven Horwitz       horwitzs@mskcc.org   
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Anjali Advani       ADVANIA@ccf.org   
United States, Oregon
Oregon Health and Sciences University Recruiting
Portland, Oregon, United States, 97239
Contact: Stephen Monette    503-494-9455    monette@ohsu.edu   
United States, Pennsylvania
University of Pittsburgh Medical Center Recruiting
Pittsburgh, Pennsylvania, United States, 15237
Contact: Sue McCann    412-864-3681    mccannsa@upmc.edu   
United States, Tennessee
Tennessee Oncology Recruiting
Nashville, Tennessee, United States, 37203
Contact    877-691-7274    asksarah@sarahcannon.com   
United States, Washington
University of Washington - Seattle Cancer Care Alliance Recruiting
Seattle, Washington, United States, 98109
Contact: Cody Hammer       chammer@seattlecca.org   
Canada, British Columbia
British Columbia Cancer Agency Recruiting
Vancouver, British Columbia, Canada, V5Z 1H6
Contact: Diego Villa    604-877-6000    dvilla@bccancer.bc.ca   
Canada, Ontario
Princess Margaret Cancer Center Recruiting
Toronto, Ontario, Canada, M5G 2M9
Contact: Lindsay Philip    416-581-7823    Lindsay.Philip@uhn.ca   
Sponsors and Collaborators
Trillium Therapeutics Inc.

Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Trillium Therapeutics Inc.
ClinicalTrials.gov Identifier: NCT02663518     History of Changes
Other Study ID Numbers: TTI-621-01
First Posted: January 26, 2016    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Trillium Therapeutics Inc.:
T-Cell
CTCL
PTCL
ALL
Rituximab
Nivolumab
TTI-621
Solid Tumor
Hematologic Malignancies
Lymphoma
Cutaneous T-Cell Lymphoma
Peripheral T-Cell Lymphoma
Acute Lymphoblastic Leukemia
CD47

Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Rituximab
Nivolumab
Immunoglobulin G
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents